International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) Analysis of CTCL Outcomes During the COVID-19 Pandemic: A Retrospective Cohort Study - Supplementary Tables
We performed a retrospective analysis of data from the electronic medical records at nine international academic medical centers in seven countries from March-October 2020, including 149 patients, actively managed with an established diagnosis of cutaneous lymphoma. Patient demographics, date of diagnosis, staging details, treatment details, delays or changes to treatment regimens, disease outcomes and COVID-19 disease history including the source of transmission was recorded. Treatment was delayed for 53.0% of patients for a mean of 3.2 months (range: 10 days to 10 months). Adjusting for age, race, biological sex, COVID-19 status and disease stage, treatment delay was associated with a significant risk of disease relapse or progression across all stages (OR 5.00 (95% CI [2.38, 11.0], p-value <0.001) and, for each additional month that a patient experienced treatment delay, the odds of disease progression increased by 37.0% (OR 1.37 (95% CI [1.14, 1.70], p-value <0.001). A total of 28 (18.8%) patients with CTCL were diagnosed with COVID-19, none acquired from outpatient office visits. Patients who contracted COVID-19 did not have a statistically significant increase in odds of disease progression compared to COVID-negative patients (OR 0.41 (95% CI [0.15, 1.08], p-value = 0.07).